SignatureFD’s Bicara Therapeutics BCAX Stock Holding History

SignatureFD’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80	Closed	-$1.04K	–	3459
2025 Q1	$1.04K	Buy	+80	New	+$1.06K	﹤0.01%	3025

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SignatureFD's BCAX Position: Q2 2025 in Review

SignatureFD sold out of Bicara Therapeutics (BCAX) in Q2 2025, closing a stake of 80 shares — an estimated $1.04K sold.

SignatureFD first reported a position in BCAX in Q1 2025 and held it in 1 quarter. The position peaked at $1.04K in Q1 2025. 106 funds tracked by Wall St. Rank hold BCAX as of Q2 2025.

SignatureFD reported no remaining Bicara Therapeutics position as of Q2 2025 after selling out during the quarter.
SignatureFD sold 80 Bicara Therapeutics shares in Q2 2025, an estimated $1.04K.
SignatureFD first reported a position in Bicara Therapeutics in Q1 2025 and held it in 1 quarter.
SignatureFD's Bicara Therapeutics position peaked at $1.04K in Q1 2025.
106 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2025.

Based on SignatureFD's 13F filing for Q2 2025, filed 16 Jul 2025.